Changes in GFAP Levels between Pre and Post Ventriculoperitoneal Shunts in Hydrocephalus Patients
Asian Journal of Medical Principles and Clinical Practice,
Introduction: Hydrocephalus is a disease that attacks the brain. Glial fibrillary acidic protein (GFAP) is a structural cytoskeleton protein expressed by astroglial and neuronal stem cells. One of the hydrocephalus treatments is the VP Shunt. After the treatment through the VP Shunt procedure, GFAP levels generally change. This study aims to determine changes in serum GFAP levels before and after insertion surgery VP Shunt in hydrocephalus patients.
Methodology: This study was an analytic observational quantitative study with a cross-sectional approach. The research subjects were patients with hydrocephalus who were treated at the Neurosurgery Section of the Regional General Hospital Dr. Moewardi from April to June 2020.
Results and Discussion: This study had 14 subjects consisting of 9 (64.3%) male subjects and 5 (35.7%) female subjects. The median value of GFAP levels before treatment was 370.5 pg/mL with the lowest level of 168 pg/mL and the highest of 1734 pg/mL. The median value of GFAP levels after VP shunt action was 249.5 pg/mL with the lowest value of 137 pg/mL and the highest of 724 pg/mL. It was found that the GFAP level before and after the VP shunt action had a significant difference with p = 0.035 (p < 0.05).
Conclusion: There is a significant difference between the GFAP serum levels before the action and after VP Shunt was performed in hydrocephalus patients.
- glial fibrillary acidic protein (GFAP)
- VP Shunt.
How to Cite
Beems T, Simons KS, Van Geel WJ, De Reus HP, Vos PE, Verbeek MM. Serum- and CSF-concentrations of brain specific proteins in hydrocephalus. Acta Neurochir (Wien). 2003;145(1):37-43.
Slusarz R, Rosińczuk-Tonderys J, Jabłońska R, Królikowska A, Kisiel A, Daniluk-Matraś I. Hydrocephalus in newborns: Clinical conditions and primary surgical treatment. Adv Clin Exp Med. 2013;22(2):237-43.
Miller JM, McAllister JP 2nd. Reduction of astrogliosis and microgliosis by cerebrospinal fluid shunting in experimental hydrocephalus. Cerebrospinal Fluid Res. 2007;4:5.
Sivagnanam M, Jha NK. Hydrocephalus: An overview, hydrocephalus; 2012.
de Oliveira AJM, Rossi J, Morales MNB, Reis BM, Pinto FCG. An unusual ventriculoperitoneal shunt complication: Catheter migration into the breast. Autops Case Rep. 2020;10(2): e2020165.
Lei J, Gao G, Feng J, Jin Y, Wang C, Mao Q, Jiang J. Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: A prospective cohort study. Crit Care. 2015;19:362.
Yang Z, Wang KK. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38(6):364-74.
Žurek J, Fedora M. The usefulness of S100B, NSE, GFAP, NF-H, secretagogin and Hsp70 as a predictive biomarker of outcome in children with traumatic brain injury. Acta Neurochir (Wien). 2012;154 (1):93-103;
Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015;32:121-30.
Hariyanto AS, Retnowati E, Turchan A. Serum glial fibrillary acidic protein levels profile in patients with severe traumatic brain injury. Indones J. Clinical Pathol. Med. 2017;24(1):24-28.
Abstract View: 35 times
PDF Download: 49 times